Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LU 70274 bacterial lipase in cystic fibrosis with pancreatic insufficiency
2006-005180-25Phase 2Completed
- Sponsor
- Nordmark Pharma
- Start
- Oct 2006
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of burlulipase in cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI), sponsored by Nordmark Pharma. Primary endpoints: Safety and tolerability and Pharmacodynamics. Started Oct 2006; status: completed.
02
Drugs
burlulipase
03
Conditions
cystic fibrosis (CF)exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2006-005180-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005180-25.